Draxis Pharma has expanded its existing contract manufacturing relationship with Johnson & Johnson Consumer Companies, Inc. to provide commercial manufacturing services for multiple non-sterile specialty semi-solid products currently marketed in the U.S.      The new contract runs to the end of 2013 and includes approximately two years of manufacturing site transfer and process validation activities followed by five years of commercial production, which is scheduled to begin in 2009. Comm...